
    
      Approximately 374 subjects with inadequately controlled T2DM on metformin will be recruited
      from North America and Europe. Subjects will be randomly assigned in a ratio of 1:1 to
      receive either bexagliflozin tablets, 20 mg, or sitagliptin tablets,100mg, once daily for 24
      weeks. Subjects will continue to take metformin for the duration of the study.
    
  